Stock Events

Stock Events

Vor Biopharma 

$20.66
58
+$0.02+0.1%Friday 07:01

Statistics

Day High
20.66
Day Low
20.66
52W High
20.82
52W Low
13.2
Volume
220
Avg. Volume
-
Mkt Cap
1.22B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Oct 30Expected
Q3 2025
Q1 2026
Q2 2026
Q3 2026
-121.63
-81.32
-41.01
-0.7
Expected EPS
-1.076246
Actual EPS
-1.45

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-695.98MNet Income

Analyst Ratings

$24.50Average Price Target
The highest estimate is ⁦31.00⁩.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VOR.BOATS. It's not an investment recommendation.
Tesla
10
TSLA
NVIDIA
10
NVDA
Apple
7
AAPL
Palantir Technologies
7
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Allogene Therapeutics
ALLO
Mkt Cap518.24M
Allogene Therapeutics competes in the CAR-T space, focusing on allogeneic cell therapies for cancer, similar to Vor's engineered cell therapies.
CRISPR Therapeutics
CRSP
Mkt Cap5.36B
CRISPR Therapeutics is involved in gene editing, a technology that is foundational to Vor Biopharma's approach to cancer treatment.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences, through its acquisition of Kite Pharma, is a leader in CAR-T therapy for cancer, directly competing with Vor's cell therapy approach.
Novartis
NVS
Mkt Cap268B
Novartis is a major player in the CAR-T cell therapy market with its product Kymriah, making it a competitor in the oncology space.
Adaptive Biotechnologies
ADPT
Mkt Cap4.52B
Adaptive Biotechnologies works on immune-driven medicine, including cancer, with a focus on cell therapy, competing with Vor's approach.
Fate Therapeutics
FATE
Mkt Cap277.98M
Fate Therapeutics is developing programmed cellular immunotherapies for cancer and immune disorders, competing in the engineered cell therapy space.
Precigen
PGEN
Mkt Cap3.06B
Precigen is a biotechnology company that develops gene and cell therapies, including for cancer, which puts it in competition with Vor.

About

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
Show More
CEO
ISIN
US9290332074

Listings

XNAS
US
VOR
BOATS
BOATS
VOR.BOATS

0 Comments

Share your thoughts

FAQs

What is Vor Biopharma stock price today?▼
The current price of VOR.BOATS is $20.66 USD — it has increased by +0.1% in the past 24 hours. Watch Vor Biopharma stock price performance more closely on the chart.
What is Vor Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Vor Biopharma stocks are traded under the ticker VOR.BOATS.
What is Vor Biopharma market cap?▼
Today Vor Biopharma has the market capitalization of 1.22B
When is the next Vor Biopharma earnings date?▼
Vor Biopharma is going to release the next earnings report on March 25, 2027.
What were Vor Biopharma earnings last quarter?▼
VOR.BOATS earnings for the last quarter are -1.45 USD per share, whereas the estimation was -1.08 USD resulting in a -34.73% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Vor Biopharma revenue for the last year?▼
Vor Biopharma revenue for the last year amounts to 0 USD.
What is Vor Biopharma net income for the last year?▼
VOR.BOATS net income for the last year is -695.98M USD.
In which sector is Vor Biopharma located?▼
Vor Biopharma operates in the Other sector.
When did Vor Biopharma complete a stock split?▼
The last stock split for Vor Biopharma was on September 19, 2025 with a ratio of 1:20.